Last reviewed · How we verify
NCT07046806: BK-AE-nC1INH
Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients
Phase 1, PHASE2 trial testing Deucrictibant XR tablet in Hereditary Angioedema (HAE) in 10 participants. Currently enrolling.
1 April 2026
Quick facts
| Lead sponsor | Institute for Asthma and Allergy |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | triple |
| Primary purpose | prevention |
| Enrollment | 10 |
| Start date | 10 March 2025 |
| Primary completion | 1 April 2026 |
| Estimated completion | 1 April 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Deucrictibant XR tablet — full drug profile →
- Placebo comparator to XR tablet — full drug profile →
- Deucrictibant 20 mg capsule — full drug profile →
- Placebo comparator to 20 mg capsule — full drug profile →
Conditions studied
- Hereditary Angioedema (HAE) — all drugs for Hereditary Angioedema (HAE) →
- Angioedema — all drugs for Angioedema →
- Bradykinin-mediated Angioedema — all drugs for Bradykinin-mediated Angioedema →
- C1 Inhibitor Deficiency — all drugs for C1 Inhibitor Deficiency →
Sponsor
Institute for Asthma and Allergy
Who can join
Adults 18 to 75, any sex, with Hereditary Angioedema (HAE) or Angioedema. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To assess the efficacy of prophylactic treatment with deucrictibant extended release (XR) tablet versus placebo in preventing angioedema attacks, and to also assess the efficacy of deucrictibant soft capsules as on-demand treatment versus placebo in achieving angioedema symptom relief during acute attacks.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07046806
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hereditary Angioedema (HAE)
Currently open trials in the same condition.
- NCT07251933 — A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple Countries · recruiting
- NCT06806618 — HAE Burden and Crisis Management · recruiting
- NCT06846398 — A Phase 2 in Adult Subjects With Hereditary Angioedema · Phase 2 · active not recruiting
- NCT05469789 — A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) · active not recruiting
- NCT05397431 — A Survey of Lanadelumab in Participants With Hereditary Angioedema · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07046806 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institute for Asthma and Allergy
- Last refreshed: 2 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07046806.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing